News | April 12, 2026
C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
Punya Salila Srivastava commends sanitation, waste management and infection control measures, while inaugurating a new G+9 undergraduate girls’ hostel
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Subscribe To Our Newsletter & Stay Updated
